ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0587

Identification of Factors Affecting Changes in the Agatston Coronary Artery Calcification Score in Maintenance Hemodialysis Patients

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Morii, Kenichi, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
  • Doi, Toshiki, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
  • Nishizawa, Yoshiko, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
  • Shigemoto, Kenichiro, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
  • Mizuiri, Sonoo, Iryo Hojin Ichiyokai Harada Byoin, Hiroshima, Japan
  • Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
Background

Coronary artery calcification (CAC) has been implicated in cardiovascular disease, one of the leading causes of death in patients on maintenance hemodialysis (MHD). The Agaston CAC score is the most widely used scoring system for CAC evaluation. The factors affecting changes in the CAC score in MHD patients remain unknown. We characterized the associations between change in Agaston CAC score and clinical parameters in MHD patients.

Methods

A total of 288 patients on hemodialysis at Ichiyokai group facilities between January 2018 to February 2021 were retrospectively analyzed. Clinical parameters and Agaston CAC scores, determined by multi-detector computed tomography, were assessed at baseline and after 1 year. Patients with Agaston CAC score ≥ 30 were enrolled. A multiple regression analysis for change in Agaston CAC score was performed. The independent variables were sex, age, Agaston CAC score, glucose, albumin-corrected serum calcium, serum phosphate, β2-microglobulin, hemoglobin, blood urea nitrogen, albumin, angiotensin-converting enzyme (ACE) inhibitor/angiotensin II receptor blocker (ARB) use, calcimimetic use, and vitamin D use.

Results

The mean change in Agaston CAC score was 205.2 ± 545.1 and the mean percentage change in Agaston CAC score was 21.2% ± 43.5%. The multiple regression analysis for change in Agaston CAC score identified Agaston CAC score (regression coefficient [RC] = 0.3795, p < 0.001), serum phosphate (RC = 0.1230, p = 0.0317), albumin-corrected serum calcium (RC = −0.1165, p = 0.0049), and ACE inhibitor/ARB use (RC = −0.1262, p = 0.0298) as significantly related factors (R2 = 0.2011, p < 0.001).

Conclusion

In patients on MHD, change in Agaston CAC score is positively associated with Agaston CAC score and serum phosphate, and negatively associated with albumin-corrected serum calcium and ACE inhibitor/ARB use.